N@N

David Macdonald Maintained (AMED) at Strong Buy with Decreased Target to $115 on, Apr 13th, 2023

David Macdonald of Truist Securities, Maintained "Amedisys, Inc." (AMED) at Strong Buy with Decreased Target from $130 to $115 on, Apr 13th, 2023.

David has made no other calls on AMED in the last 4 months.

There are 8 other peers that have a rating on AMED. Out of the 8 peers that are also analyzing AMED, 3 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Scott Fidel of "Stephens & Co." Reiterated at Hold and Held Target at $103 on, Tuesday, March 14th, 2023
• Steve Valiquette of "Barclays" Initiated at Hold and Held Target at $93 on, Monday, March 13th, 2023
• Whit Mayo of "SVB Leerink" Maintained at Hold with Decreased Target to $85 on, Thursday, January 5th, 2023

These are the ratings of the 5 analyists that currently disagree with David

---

• Bill Sutherland of "Benchmark" Reiterated at Strong Buy and Held Target at $115 on, Tuesday, March 14th, 2023
• Jonathan Yong of "Credit Suisse" Reiterated at Buy and Held Target at $115 on, Monday, February 27th, 2023
• Ben Hendrix of "RBC Capital" Maintained at Buy with Decreased Target to $111 on, Tuesday, February 21st, 2023
• Mark Miller of "Benchmark" Maintained at Strong Buy with Decreased Target to $115 on, Thursday, February 16th, 2023
• Colin Rusch of "Oppenheimer" Maintained at Buy with Decreased Target to $125 on, Thursday, January 19th, 2023

Contributing Sources

---